Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment

Campbell, Rachel; King, Madeleine; Ross, Tanya; Cohen, Paul A.; Friedlander, Michael; Webb, Penelope M.

doi:10.1016/j.ygyno.2021.08.022

Cited by 6 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As such, these two symptoms could be removed from the MOST-Chemo index, scored separately and labeled 'MOST-NTx'. This modified scoring approach for MOST-Chemo/MOST-NTx has recently been adopted in the development of a new version of MOST designed for surveillance of symptoms following first line treatment for ovarian cancer [26].…”

Section: Discussionmentioning

confidence: 99%

“…To facilitate triaging for psychological support, threshold scores have recently been identified for MOST items that signify clinically important anxiety and depression. Specifically, scores above 3 on 'depression (feeling sad)' and 4 on 'anxiety (feeling worried)' indicate clinically important symptoms requiring further assessment/referral by the treating oncologist [26].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Campbell

Costa

Stockler

et al. 2022

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Campbell

Costa

Stockler

et al. 2022

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

“…It has 24 items and 5 multi-item scales: MOST-Well-being, MOST-Abdo (measuring abdominal symptoms), MOST-Psych (measuring psychological wellbeing), MOST-Chemo (measuring chemotherapy-related symptoms) and MOST-DorT (measuring disease or treatment-related symptoms) [ 26 , 27 ]. An updated version of the MOST for use during follow-up/surveillance (MOST-S-26) has also recently been developed and validated [ 28 ].…”

Section: Main Textmentioning

confidence: 99%

Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges

Lefkovits,

Heriot,

Sporik

et al. 2024

BMC Health Serv Res

View full text Add to dashboard Cite

As medical treatment increasingly focuses on improving health-related quality of life, patient-reported outcome measures (PROMs) are an essential component of clinical research. The National Gynae-Oncology Registry (NGOR) is an Australian clinical quality registry. A suitable PROM was required for the NGOR ovarian cancer module to complement clinical outcomes and provide insights into outcomes important to patients. Our narrative review aimed to identify existing ovarian cancer-specific PROMs and ascertain which tool would be most appropriate for implementation into the NGOR ovarian cancer module.A literature review of Cochrane Library, Embase, MEDLINE and PubMed databases was performed to identify existing ovarian cancer-specific PROM tools. A steering committee was convened to (1) determine the purpose of, and criteria for our required PROM; and (2) to review the available tools against the criteria and recommend the most appropriate one for implementation within the NGOR.The literature review yielded five tools: MOST, EORTC QLQ-OV28, FACIT-O, NFOSI-18 and QOL-OVCA. All were developed and validated for use in clinical trials, but none had been validated for use in clinical quality registry. Our expert steering committee pre-determined purpose of a PROM tool for use within the NGOR was to enable cross-service comparison and benchmarking to drive quality improvements. They identified that while there was no ideal, pre-existing, ovarian cancer-specific PROM tool for implementation into the NGOR, on the basis of its psychometric properties, its available translations, its length and its ability to be adapted, the EORTC tool is most fit-for-purpose for integration into the NGOR.This process enabled identification of the tool most appropriate to provide insights into how ovarian cancer treatments impact patients’ quality of life and permit benchmarking across health services.

show abstract

“…45 Another version of MOST (MOST-S26) was recently developed and validated for the purpose of symptom surveillance following first-line treatment for ovarian cancer to complement clinical follow-up. 46 Of note, all MOST versions focus exclusively on symptoms and global well-being and are not HRQL measures. Thus, MOST should be administered in combination with relevant FACT or EORTC measures if HRQL is an outcome of interest.…”

Section: Pro Measures For Ovarian Cancermentioning

confidence: 99%

Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

Campbell¹,

King²,

Stockler³

et al. 2023

PROM

Self Cite

View full text Add to dashboard Cite

Patient-reported outcomes (PROs) provide a valid, standardized way of assessing symptoms, adverse events and the subjective benefit of treatment from the patient's perspective. Assessment of PROs is critical in ovarian cancer due to the high morbidity of the disease and its treatments. Several well-validated PRO measures are available to assess PROs in ovarian cancer. Their inclusion in clinical trials can provide evidence on the benefits and harms of new treatments based on patients' experiences to guide improvements in clinical practice and health policy. Aggregate PRO data collected in clinical trials can be used to inform patients about likely treatment impacts and assist them to make informed treatment decisions. In clinical practice, PRO assessments can facilitate monitoring of a patient's symptoms throughout treatment and follow-up to guide their clinical management; in this context, an individual patient's responses can facilitate communication with their treating clinician about troublesome symptoms and their impact on their quality of life. This literature review aimed to provide clinicians and researchers with a better understanding of why and how PROs can be incorporated into ovarian cancer clinical trials and routine clinical practice. We discuss the importance of assessing PROs throughout the ovarian cancer disease and treatment trajectory in both clinical trials and clinical practice, and provide examples from existing literature to illustrate the uses of PROs as the goals of treatment change in each setting.

show abstract

Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment

Cited by 6 publications

References 27 publications

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer

Incorporating patient-reported outcome measures (PROMs) into a clinical quality registry (CQR) for ovarian cancer: considerations and challenges

Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice

Contact Info

Product

Resources

About